Raltegravir News and Research

RSS
Merck reports $342 million net income for 2010 third quarter

Merck reports $342 million net income for 2010 third quarter

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Merck's ROTATEQ vaccine receives Prix Galien USA 2010 Award for Best Biotechnology Product

Merck's ROTATEQ vaccine receives Prix Galien USA 2010 Award for Best Biotechnology Product

Raltegravir could be valid target against all Herpesviridae

Raltegravir could be valid target against all Herpesviridae

Merck and Bill & Melinda Gates Foundation commit additional $60M to support Botswana's ACHAP

Merck and Bill & Melinda Gates Foundation commit additional $60M to support Botswana's ACHAP

Merck reports strong bottom-line performance in second quarter

Merck reports strong bottom-line performance in second quarter

HIV drug can raise the risk of heart disease: Study

HIV drug can raise the risk of heart disease: Study

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Merck hosts R&D and Business Briefing

Merck hosts R&D and Business Briefing

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

Merck announces global sales of $27.4 billion for full-year 2009

Merck announces global sales of $27.4 billion for full-year 2009

Breakthrough in HIV research leads to better treatment potential

Breakthrough in HIV research leads to better treatment potential

AHF to host protest targeting Merck over the steep price for its key HIV/AIDS drug, Isentress

AHF to host protest targeting Merck over the steep price for its key HIV/AIDS drug, Isentress

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

MSD's ISENTRESS approved by the EU Commission for treating HIV-1 infection in adult patients

MSD's ISENTRESS approved by the EU Commission for treating HIV-1 infection in adult patients

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

Tobira Therapeutics presents TBR-652 in vitro data for treating HIV at the 49th ICAAC

Tobira Therapeutics presents TBR-652 in vitro data for treating HIV at the 49th ICAAC

Criminal pricing of Merck’s HIV/AIDS drug Isentress challenged by the AIDS Healthcare Foundation

Criminal pricing of Merck’s HIV/AIDS drug Isentress challenged by the AIDS Healthcare Foundation